CORE awarded $50K breast cancer health inequities research grant

August 1, 2023

Share this Article
Facebook
Twitter
LinkedIn

A doctor providing a woman with a mammogram

Back to CORE's website

The Providence Center for Outcomes Research & Education (CORE) has been awarded a $50,000 grant to advance its growing body of research on breast cancer health inequities.

The funding from the Preparedness and Treatment Equity Coalition (PTEC) and Gilead Sciences will help CORE examine the pathways by which healthcare experiences, including discrimination in the healthcare setting, contribute to gaps in mammography. CORE researchers will also assess the ways in which these experiences may differ for those included and excluded in health system breast cancer screening metrics.

“We are excited to continue our important work of understanding and ultimately addressing the underlying factors that contribute to disparities in breast cancer outcomes among people of color and other groups experiencing inequities in the U.S. health system,” said Monique Gill, a research scientist at CORE.

CORE is among three U.S. research teams receiving similar awards from PTEC. Read the full press release at PTEC’s website: https://ptechealth.org/bc-inequities-press-release

Related resources

Blog post: Addressing language disparities in breast cancer screening
Learn more about the Preparedness & Treatment Equity Coalition

Providence physician receives lifetime achievement award

The American Society of Nephrology is honoring Dr. Katherine Tuttle with one of health care research’s most...

Breast cancer survivor, artist gives back to Providence

Portland painter credits the support of Providence providers and creating art for helping her recover and h...

Other content in this Stream

The evolution of cancer immunotherapy: Dr. Urba shares his insights

CORE awarded $50K breast cancer health inequities research grant

Previous Article

Next Article

Other content in this Stream

Providence Cancer Institute chief medical officer Walter J. Urba, M.D., Ph.D. talks about the evolution of immunotherapy in the past three decades and his vision for its future.

Over the next three years, this study seeks to identify the patterns of access and use of cancer services among high-risk patients to understand how to guide them toward quality care.

Providence researchers conducted over 2400 studies in 2023, according to the 2023 Providence Research Network Annual Report

Learn more about a clinical trial for men with metastatic prostate cancer.

In North Puget Sound, Providence Swedish has implemented solutions to address opioid overdoes, including participating in grant programs and research to discover addiction treatments that work.

A joint study between Providence, Microsoft and the University of Washington detailing work to create a novel AI-powered pathology model has been published in Nature.

Explore three innovative studies targeting uveal melanoma, melanoma and head and neck squamous cell carcinoma. Learn why these studies offer hope for more effective cancer treatments.

The annual meeting of cancer experts is a platform to collaborate and accelerate cancer research findings into clinical applications.

The largest study of angiosarcoma published to date, co-authored at Providence, describes the incidence and presentation patterns of angiosarcoma, a rare but potentially deadly cancer.

The 2023 Providence Research Network annual report, released on Clinical Trials Day 2024, highlights the breadth and impact of research at Providence.

Two stories of how, together with our industry partners and patients, Providence is working to make the latest trials available to more people who could benefit from them.

Providence St. Jude Crosson Cancer Institute oncologists are aggressively pursuing new answers to metastatic prostate cancer, including research into an innovative immunotherapy called AMG 509.

When the SpaceX mission returns to earth in April, there will be 80 mice onboard who have spent a month living at the International Space Station. The rodents represent the first investigational ophth

Researchers at Providence Cancer Institute are exploring a range of innovative approaches to targeting human papillomavirus-positive head and neck squamous cell cancer.

In a new clinical trial open at Providence Cancer Institute, the therapy IGM-8444 aims to promote apoptosis, potentially slowing down the growth of DR5-positive tumor cells.

A recent article in TIME magazine features research conducted by CORE and the Providence Research Network into the condition known as long COVID.

Four patients are among first in the nation to undergo groundbreaking pulsed field ablation procedure.

The FDA just approved a new immunotherapy for advanced melanoma. Dr. Walter Urba shares how Providence’s participation in the clinical study shows our standing as a global leader in immuno-oncology.

Two early phase trials available at Providence Cancer Institute to evaluate escalating doses of different potential cancer treatments in patients with advanced solid tumors.

The Food and Drug Administration has approved an adoptive cell therapy for adult patients with melanoma that has spread to other parts of the body (metastatic).